Tilray Expands Medical Cannabis Product Offering in Australia

NEW YORK and SYDNEY, Jan. 25, 2022 – PRESS RELEASE – Tilray Brands Inc., a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live its very best life, announced the expansion of its medical cannabis product offering in Australia and a new medical cannabis e-learning platform for health care providers.

Denise Faltischek, head of international and chief strategy officer, said, “Tilray is transforming the industry globally with our highly scalable footprint and portfolio of diverse cannabis products. As medical cannabis demand increases worldwide, we remain committed to providing health care professionals and patients with safe and reliable access to the highest-quality medical cannabis products.”

Faltischek added, “After listening to patient feedback and leveraging learnings from our operations in Germany, we are excited to be introducing new products in Australia that meet consumer needs.”

Tilray's product offering in Australia approved under the Therapeutic Goods Administration (TGA) Special Access and Authorized Prescriber Scheme is centered around its whole flower options ranging from balanced 1:1 whole flower (THC 10, CBD 10), including mid-range (17), and high-THC (25) varieties of 15g bag GMP-certified medical cannabis whole flower. 

George Polimenakos, general manager, Tilray Australia and New Zealand, said, "We are committed to providing reliable access to patients in need with pharmaceutical-grade medical cannabis products and are pleased to be expanding our medical cannabis offerings in Australia."

Polimenakos added, “On a related note, cannabis education is paramount to everything we do, and [we] are therefore excited to offer health care professionals with the tools they need to learn about cannabis through our new e-learning platform.”

Tilray’s new medical cannabis educational platform for health care professionals is built on the importance of understanding the benefits derived from medical cannabis use. To date, Tilray has successfully introduced multiple medical cannabis workshops across Australia and New Zealand, educating hundreds of health care practitioners in 2021.

In addition to supplying hospitals and pharmacies, Tilray is a proud partner with several leading research institutions, including the Murdoch Children's Research Institute in Australia, studying the effectiveness of Tilray medical cannabis as a treatment for pediatric patients with Intellectual Disabilities suffering from Severe Behavioral Problems; a clinical trial in partnership with The Government of New South Wales and University of Sydney Chris O'Brien Lifehouse to develop a novel treatment for chemotherapy-induced nausea, and a study led by the University of Sydney examining the effects of driving under the influence of cannabis.

Today, Tilray is one of the leading providers of GMP-certified medical cannabis to patients, physicians, pharmacies, hospitals, governments, and researchers across the globe.

For more information about Tilray medical cannabis in Australia and New Zealand, visit: https://www.tilray.com.au/

For more information about the Tilray medicinal cannabis workshops in Australia, visit: https://tilray.medihuanna.com/